Carvedilol Tablet, Film Coated
Product Images NDC 43063-126

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 43063-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063126 Label (43063126)

Label for Carvedilol USP 3.125 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc., featuring an NDC of 43063-126-93. The label indicates a package size of 180 tablets and includes a warning to keep out of reach of children, reorder number 100643, and sample lot with expiration date 01/50. The design incorporates green highlights and barcodes.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A line graph titled 'Survival Analysis for COPERNICUS (Intent-to-Treat)' comparing percent mortality over time in months between two groups: Placebo and Carvedilol. The graph shows mortality increasing over 21 months, with the Carvedilol group having a lower mortality rate than the Placebo group. A p-value of 0.004 is indicated.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot showing effects on mortality hazard ratios for various subgroups in the COPERNICUS study. Subgroups include men, women, age groups, racial groups, diabetic status, ischemic condition, heart rate, systolic blood pressure categories, and spironolactone use, compared against all patients. Each subgroup is represented with a point estimate and confidence interval on a hazard ratio scale from 0 to 2.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A line graph titled 'Survival Analysis for CAPRICORN (Intent-to-Treat)' depicting % mortality over 24 months. The graph compares two groups: Placebo and Carvedilol, with % mortality on the Y-axis and months on the X-axis. A P-value of 0.03 is indicated.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A forest plot titled 'Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios for various patient subgroups. The chart compares subgroups such as age, sex, timing of randomization post-MI, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA for MI, heart failure status, use of diuretics, presence of angina, hypertension, diabetes, heart rate, and systolic blood pressure. Hazard ratios with confidence intervals are plotted to depict mortality effects across these subgroups.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure diagram of the active ingredient Carvedilol, showing the molecular arrangement of atoms and bonds typical for this pharmaceutical compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.